

CURRICULUM VITAE

Gregory Clarke Townsend, M.D.

I. Personal Information



Business Address:

PO Box 800545
Division of Infectious Diseases
Department of Internal Medicine
University of Virginia Health System
Charlottesville, VA 22908-0545
Telephone: (434) 982-4471
FAX: (434) 982-3992
e-mail: gct2r@virginia.

Medical Licensure

Virginia _____

**APPEARS THIS WAY
ON ORIGINAL**

II. Education

COLLEGE EDUCATION

College of William and Mary

Williamsburg, VA

Bachelor of Science (Biology) 1980

MEDICAL EDUCATION

University of Virginia School of Medicine

Charlottesville, VA

Doctor of Medicine 1986

III. Postgraduate Medical Education

RESIDENCY TRAINING

Internal Medicine/Pediatrics

West Virginia University Hospitals

Morgantown, WV

July 1986 - June 1990

FELLOWSHIP TRAINING

Infectious Diseases

University Of Virginia Affiliated Hospitals

Veterans Administration Medical Center

Salem, VA

Infectious Diseases

July 1990 - June 1991

Infectious Diseases

University of Virginia Health Sciences Center

Charlottesville, VA

July 1991 - June 1993

IV. Academic Appointments

2004-present

Associate Professor of Internal Medicine

Division of Infectious Diseases

University of Virginia, Charlottesville, VA

1998-2004

Assistant Professor of Internal Medicine

Division of Infectious Diseases

University of Virginia, Charlottesville, VA

1994-1998

Research Assistant Professor of Internal Medicine

Division of Infectious Diseases

1993-1994

University of Virginia, Charlottesville, VA
Clinical Instructor of Internal Medicine
Division of Infectious Diseases
University of Virginia, Charlottesville, VA

V. Honors and Awards

Outstanding Resident In Ambulatory Care, Internal Medicine
West Virginia University Hospitals
1987

Outstanding Resident In Ambulatory Care, Pediatrics
West Virginia University Hospitals
1988

Alpha Omega Alpha Medical Honor Society
University of Virginia Chapter
1996

AIDS in Education Award
AIDS/HIV Services Group
1998

Clinical Excellence Award
University of Virginia Department of Internal Medicine
2000-2001

Teaching Award
University of Virginia Department of Internal Medicine
2002-2003

Award For Excellence In Teaching
University of Virginia School of Medicine
2003

VI. Professional Affiliations

Member, American College of Physicians
Fellow, American Academy of Pediatrics

Member, Infectious Diseases Society of America

VII. Board Certification

Diplomate, American Board of Internal Medicine (Infectious Diseases)

Diplomate, American Board of Pediatrics (Infectious Diseases)

VIII. Research

- | | |
|-----------|---|
| 1991-1998 | The roles of inflammatory mediators (interleukin-1, interleukin-6, interleukin-8, platelet activating factor, et al) in an in vivo animal model of the pathophysiology of bacterial meningitis. |
| 1992-1998 | The establishment of an immortal human cerebral microvascular endothelial cell line for in vitro modeling of bacterial meningitis. |

IX. Teaching Activities

Regularly Scheduled Activities

- | | |
|--------------|---|
| 1993-present | Founder and organizer, "Infectious Diseases Journal Club", 1 st and 3 rd Fridays of every month, 10-20 participants from Infectious Diseases Division and Dept. of Microbiology |
| 1993-present | Lecturer, Infectious Diseases didactic lecture series, 2-3 hours/year, 4-6 fellows each session |
| 1993-1997 | Mentor, Medical Academic Advancement Program |
| 1994-present | Supervisor and mentor, "Practice of Medicine-1" History & Physical Exam, 8 hours/year, 1 student |
| 1996-present | Tutorial group leader, "Introduction to Clinical Medicine"/ "Practice of Medicine-2", 56 hours/year, 6 students per semester |
| 1996-present | Problem set group leader, "Introduction to Clinical Medicine"/ "Practice of Medicine-2", 6 hours/year, 12-15 students per session |

1996-2000	Lecturer, Epidemiology graduate course, 2 hours/year, 30 students
1998-2001	Lecturer, Ambulatory Internal Medicine Infectious Diseases lecture for Internal Medicine residents, 24 hours/year, 6-8 residents each session
1998-present	Section leader, Ambulatory Internal Medicine Infectious Diseases workshop for 3 rd year medical students, 12 hours/year, 10-12 students each session
1998-present	Supervisor and mentor, "Biomedical Ethics" undergraduate course, 100 hours/year, 1 student each semester
1998-present	Lecturer, Graduate Nursing Pathophysiology course, 2 hours/year, 30-40 students
2001-present	"Practice of Medicine-2" Infectious Diseases section leader (responsible for coordinating tutorials, updating cases and handouts with complete revision of handouts in 2002)
2002-present	Lecturer, "Medical Anthropology" undergraduate course, 1 hour/year, 80 students

Conferences, Grand Rounds, etc.

6/99	"HIV Vaccine: New Hope or Phantom Menace", Medical Grand Rounds, University of Virginia
4/01	"HIV Update", Western State Grand Rounds, Staunton, VA
7/01	"Approach to the AIDS Patient With...", Medical Grand Rounds, University of Virginia
9/02	"HIV in Minorities", Community Minority Health Initiative symposium, Charlottesville, VA
10/02	"HIV & Substance Abuse", Region 10 Community Services Board symposium, Culpeper, VA

- 11/02 “HIV & Psychiatry”, Psychiatry Grand Rounds,
Charlottesville, VA
- 5/02 “Infectious Diseases Update”, Rockingham Memorial
Hospital, Harrisonburg, VA
- 6/02 “HIV in Preadolescents & Adolescents”, Region 10
Community Services Board symposium, Staunton, VA

X. Clinical Activities

- 1993-present Faculty attending on Internal Medicine inpatient wards, 1-3
months/year (4 residents, 2 fellows each rotation)
- 1993-present Faculty attending on Infectious Diseases inpatient
consultation service 1-2 months/year (1 fellow, 1-3 residents,
1-5 students each rotation)
- 1993-1994 Faculty attending in University Medical Associates clinic
- 1993-present Faculty attending in Infectious Diseases clinic, 3-6 half-
days/week (1-2 fellows, 0-2 residents, 0-1 students, 2 nurse
practitioners per session)
- 1997-present Faculty attending in Infectious Diseases Telemedicine
clinics, 2 half-days per month
- 1997-present Associate Director, Infectious Diseases Clinic
- 1998-2000 Faculty attending on Antimicrobial Surveillance Team, 8 –10
weeks/year
- 1998-present Director, Ryan White Program
- 1998-present Collaboration with Dept. of Obstetrics and Gynecology to
create and maintain HIV Family Centered Clinic to provide
medical and gynecologic care for HIV-infected women and
their children

2002-present Founder and organizer, clinical staff meetings 2nd and 4th
Fridays of each month

XI. Other Professional Activities

1995-1998 Member, AIDS/HIV Services Group Board of Directors,
Charlottesville, VA

1998-present Collaborations with regional AIDS Resource Center, Region
10 Community Services Board, AIDS/HIV Services Group,
the Way of the Cross Agency to hold HIV testing and
counseling sessions

1998-present Collaborations with local health departments to perform HIV
testing and counseling on migrant workers on weekly basis
in-season

1999-present Web Alert Editor, Current Infectious Disease Reports

XII. Committees

University

1998-2000 Antimicrobial Utilization Committee

1999-present University of Virginia Infection Control HIV Subcommittee

2003-present Human Investigation Committee

State

1996-present Virginia Health Department AIDS Drug Assistance Program
Committee

XIII. Grant Support

1. Robert Wood Johnson Foundation Minority Medical Faculty
Development Program
Role on Project: P.I.
Dates: 7/94-6/98
Total annual direct costs: _____
Total direct costs: _____

The major goal of this project was to investigate the roles of immunologic mediators in the pathophysiology of bacterial meningitis

2. Health Resources and Services Administration Ryan White Title IIIb, "Early Intervention Services/Primary Care"

Role on Project: P.I.

Dates: 7/98-present (renewal 7/01)

Total annual direct costs: \$487,623

Total direct costs: \$2,307,632

The major goal of this project is to provide state-of-the-art primary care services and HIV management to individuals infected with HIV, and to provide testing, education, and prevention services to individuals at risk

3. Northwest Virginia AIDS Consortium, "Outreach services grant"

Role on Project: P.I.

Dates: 10/01-present

Total annual direct costs: _____

Total direct costs: _____

The major goal of this project is to identify HIV-infected individuals lost to care from the Infectious Diseases clinic and then to contact them and ascertain the reasons and assure that they are receiving care elsewhere or to encourage them to return to the clinic

XIV. Publications and Abstracts

Original Research – Peer Reviewed Publications

1. **Townsend** GC, Scheld WM. Platelet-activating factor augments meningeal inflammation elicited by *Haemophilus influenzae* lipooligosaccharide in an animal model of meningitis. Infect Immun 1994;62:3739-44.

2. Buster BL, Weintrob AC, **Townsend** GC, Scheld WM. The potential role of nitric oxide in the pathophysiology of experimental bacterial meningitis in the rat. Infect Immun 1995;63:3835-9.

Conference Proceedings

1. **Townsend** GC, Scheld WM. Platelet-activating factor (PAF) augments, but does not initiate, experimental meningeal inflammation (MI) (abstract 952). In: Proceedings of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C.: American Society for Microbiology. 1992:269.

2. Weintrob A, Buster B, **Townsend G**, Scheld WM. The effect of L-histidine on blood-brain barrier permeability during experimental *Haemophilus influenzae* meningitis (abstract 795). In: Proceedings of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C.: American Society for Microbiology. 1993:265.
3. **Townsend GC**, Musso GF, Starzyk RM, Scheld WM. *Bordetella pertussis* filamentous hemagglutinin (FHA) peptide F20 reduces subarachnoid space inflammation (SASI) in experimental *Haemophilus influenzae* type B (Hib) bacterial meningitis (BM) (abstract G59). In: Proceedings of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C.: American Society for Microbiology. 1994:141.
4. Weintrob A, **Townsend G**, Buster B, Scheld WM. The potential role of nitric oxide (NO) in the pathophysiology of bacterial meningitis (BM) (abstract G60). In: Proceedings of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C.: American Society for Microbiology. 1994:142.
5. Buster BL, Weintrob AC, **Townsend GC**, Scheld WM. The potential role of nitric oxide in the pathophysiology of pneumococcal meningitis in the rat (abstract B21). In: Proceedings of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C.: American Society for Microbiology. 1995:29.
6. Buster BL, Weintrob AC, **Townsend GC**, Scheld WM. The effect of a nitric oxide synthase inhibitor on the pathophysiology of bacterial meningitis in the rat (abstract B20). In: Proceedings of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C.: American Society for Microbiology. 1995:29.
7. **Townsend GC**, Scheld WM. Antibody against intercellular adhesion molecule-1 (ICAM-1) decreases subarachnoid space (SAS) inflammation in experimental *Haemophilus influenzae* type b (Hib) bacterial meningitis (BM) (abstract B32). In: Proceedings of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C.: American Society for Microbiology. 1996.

8. O'Hanley JR, Buster BL, **Townsend** GC, Scheld WM. The effect of dicumarol on blood-brain barrier pathophysiology and cerebrospinal fluid pleocytosis in experimental bacterial meningitis (abstract B33). In: Proceedings of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C.: American Society for Microbiology. 1996.
9. **Townsend** GC. Leukocyte-endothelial cell interactions in bacterial meningitis (abstract S66). In: Proceedings of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C.: American Society for Microbiology. 1996.
10. **Townsend** GC, Scheld WM. Microbial-leukocyte-endothelial cell interactions and altered permeability of the blood-brain barrier during meningitis. In: Proceedings of the European Conference on Clinical Microbiology and Infectious Diseases, 1997.
11. Parrack CB, Buster BL, **Townsend** GC, Scheld WM. Peptidoglycan and lipopolysaccharide initiate bacterial meningitis by disparate pathways in the rat (abstract B69). In: Proceedings of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C.: American Society for Microbiology. 1997.

Reviews

1. **Townsend** GC, Scheld WM. Bacterial meningitis: recognition and treatment. Hospital Medicine 28:108-23, 1992.
2. **Townsend** GC, Scheld WM. Adjunctive therapy for bacterial meningitis: rationale for use, current status, and prospects for the future. Clin Infect Dis 1993;17 (Suppl 2):S537-49.
3. **Townsend** GC, Scheld WM. Review of current therapy for nosocomial pneumonia. Curr Opin Infect Dis 1995;8:98-104
4. **Townsend** GC, Scheld WM. Selected issues in the management of pulmonary infections in the hospitalized patient. Infect Dis Clin Practice (in press).
5. **Townsend** GC, Scheld WM. Microbe-endothelium interactions in blood-brain barrier permeability during bacterial meningitis. ASM News 1995;61:294-8.

6. **Townsend** GC, Scheld WM. Clinically important trends in bacterial meningitis. *Infect Dis Clin Pract* 1995;4:423-30.
7. **Townsend** GC, Scheld WM. In vitro modeling of the blood-brain barrier. *Trends Microbiol* 1995;11:441-5.
8. **Townsend** GC, Scheld WM. Nosocomial pneumonia. *Curr Opinion Infect Dis* 1995;8:98-104.
9. **Townsend** GC, Scheld WM. Antiinflammatory therapy in bacterial meningitis: rationale and practice. *Clin Immunother* 1996;5:223-9.
10. **Townsend** GC, Scheld WM. The use of corticosteroids in the management of bacterial meningitis in adults. *J Antimicrob Chemother* 1996;37:1051-61.
11. **Townsend** GC, Scheld WM. Adjunctive corticosteroids for adult bacterial meningitis. *Infect Med* 1995;12:701,702,706-10.
12. **Townsend** GC, Mandell GL. The new antibiotics, 1997. *Virginia Medical Quarterly* 1997;124:108-111.
13. **Townsend** GC, Wispelwey B. Meningitis: diagnosis and treatment. *Curr Practice Medicine* 1999;166:573-82.
14. Mandell GL, **Townsend** GC. New and emerging infectious diseases. *Trans Am Clin Climatol Assoc* 1998;109:205-16.
14. **Townsend** GC. Nosocomial pneumonia. *Clin Microbiol Rev* (submitted for publication).
15. **Townsend** GC, Newberry Y, Pakyz A. HIV in women. *Journal of Pharmacy Practice* 2003;16(3):170-181

Book Chapters

1. **Townsend** GC, Scheld WM. Bacterial meningitis. In: *Conn's Current Therapy* 1995. Rakel RE (ed). W. B. Saunders Company 1995; Philadelphia, pp. 99-103.

2. **Townsend GC, Scheld WM.** Pathophysiology of alterations in the blood-brain barrier during bacterial meningitis. In: *In Defense of the Brain; current concepts in the immunopathogenesis and clinical aspects of CNS infections*. P. K. Peterson and J. S. Remington (ed.). Blackwell Publishing 1997.
3. **Townsend GC, Scheld WM.** Infections of the central nervous system. In: *Advances in Internal Medicine*. Schrier RW et al (eds). Mosby-Year Book, Inc. 1998; Baltimore, pp. 403-447.
4. **Townsend GC, Scheld WM.** Nitric oxide in bacterial meningitis. In: *Nitric Oxide and Infection*. Fang F (ed). Kluwer Academic/Plenum Publishers 1999; New York, pp. 417-28.
5. **Townsend GC.** Brain abscess and other focal pyogenic infections. In: *Infectious Diseases* (Armstrong D and Cohen J, eds). Mosby 1999; St. Louis, pp.17.1-17.8.
6. **Townsend GC, Scheld WM.** Adult rat model of meningitis. In: *Handbook of Animal Models of Infection*. Zak O and Sande M (eds). Academic Press 1999; pp. 627-30.
7. **Townsend GC, Wispelwey B.** Meningitis. In: *Current Practice of Medicine 1999*. Turck M (ed). Current Medicine, Inc. 1999; pp. 573-82.
8. **Townsend GC.** Brain abscess and other focal pyogenic infections. In: *Infectious Diseases* (Armstrong D and Cohen J, eds). Mosby 2003; St. Louis (in press).
9. **Townsend GC.** The Infectious Diseases Physician and Digital Media. In: *Principles and Practice of Infectious Diseases* (Mandell GL, Bennett JE, Dolin R, eds) 6th edition (submitted for publication).

XV. Invited Speaker

36th Interscience Conference on Antimicrobial Agents and Chemotherapy.
Washington, D.C.: American Society for Microbiology 1996.